What’s News in Markets: Amgen’s Prognosis, Quantum Boost, iPhone Makeover

Why did a failed Novartis drug trial tank Amgen’s shares? And how is taxpayer money funding quantum-computing companies? Plus, will people pay $2,000 for a foldable iPhone? Host Imani Moise discusses the biggest stock moves of the week and the news that drove them.

Sign up for the WSJ's free Markets A.M. newsletter (wsj.com/newsletters/markets-am?mod=WSJ_WNPOD).

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.